Stemtech, Viago And Eevia Health Announce Proposed RTO

Stemtech Corporation (OTCQB:STEK), a US-based company announced this past Tuesday its planned merger (“Merger”) with Seacret Direct, LLC (“VIÁGO”) and now announces a proposal for a Reverse Takeover (RTO) of Eevia Health Plc (“Eevia”), a Finnish producer of bioactive organic Arctic plant extracts and nutraceuticals and has its common stock listed on the Swedish Spotlight Stock Market under the symbol “EEVIA”.

This strategic RTO marks a major milestone in the evolution of the combined companies, intending to create a vertically integrated health, wellness, and lifestyle entity that manufactures its own products and is positioned for significant growth in the global marketplace.

Reverse Takeover Structure and Valuation:

Under the proposed RTO, Eevia will acquire the assets and assume the liabilities of Stemtech and, upon completion of the Merger, VIÁGO by Eevia issuing new shares, resulting in Stemtech owning approximately 85% of Eevia, with the remaining 15% of the Eevia shares owned by its existing shareholders. The final valuation, share issuance, and terms are subject to conditions, including the negotiation of the definitive agreements, a third -party valuation, and the completion of the due diligence process.

Synergies and Strategic Rationale: 

Stemtech and VIÁGO have identified Eevia’s advanced production facility in Kauhajoki, Finland, as a planned significant resource for manufacturing their expanding product portfolio, which includes stem cell nutrition supplements for humans and pets, as well as VIÁGO’s cosmetic and nutritional products under the VIÁGO brand. Stemtech expects that Eevia’s expertise in sustainable production will add significant value to the combined entity’s mission of delivering high-quality health and wellness solutions.

Driving Innovation and Market Expansion:

Stemtech Corporation: Stemtech and VIÁGO brings a powerful combination of stem cell nutrition products and a diverse lifestyle and wellness membership offering that spans travel, health, beauty, and events. With over 250,000 affiliated members, customers and independent representatives, it operates in 40+ countries, including the Americas, Asia, Africa, and Europe.

Eevia Health: Founded in 2017, Eevia Health specializes in producing natural bioactive ingredients with an emphasis on sustainability. Their organic Arctic products are sold to corporate customers and include ingredients for manufacturers of dietary supplements, food, and cosmetics on a global basis.

These proposed business combinations enable Stemtech and VIÁGO to leverage Eevia’s capabilities for expanded production while growing its business presence in Europe.

The proposed RTO is expected to align with Stemtech and VIÁGO’s strategy of optimizing manufacturing processes and increasing product output to meet the growing demand for wellness, lifestyle, and nutritional products. The proposed RTO should expand Eevia’s operations, creating significant efficiencies to increase financial performance. The transaction target significant increase of consolidated revenues in 2025, with strategic synergies.